ArticleScientific reports2026
Hypertension and other comorbidities associated with increased mortality in hospitalized adult patients with COVID-19 in spain: a descriptive, retrospective, nationwide study.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Despite the high rates of COVID-19 vaccination achieved in Spain, work must continue to ensure that vulnerable populations are protected. The aim of this study was to identify comorbidities associated with increased mortality in adult patients hospitalized with COVID-19 in Spain. We obtained all hospital discharge data for COVID-19-related diseases from January 2020 to December, 2021. Specific data were collected on potential poor prognostic risk factors, such as solid tumours, haematological malignancies, immunodeficiencies, diabetes, hypertension, cardiopulmonary disease, chronic lower respiratory tract disease, COPD, or liver disease. There were 751,598 hospitalizations for COVID-19 in adults in Spain between 2020 and 2021, with a hospitalization rate of 958.57 per 100,000, reaching 4439.36 hospitalizations per 100,000 persons in patients ≥ 80 years. The case fatality rate in adults hospitalized with COVID-19 was 13.7%, and it exceeded 24% in those ≥ 80 years. Hospitalized adult patients with COVID-19 with any of the comorbidities studied were 4.70 times more likely to die than those without comorbidities. The risk of death increased by a factor of 6.25 for patients with solid tumours, 7.98 for patients with haematologic malignancies, 4.81 for patients with diabetes or 4.22 for patients with hypertension. When stratified by age, comorbidities conferred the largest relative mortality increases in younger adults (e.g., hypertension in 60–64-year-olds: CFR 7.34%, OR 3.13 [95% CI 2.79–3.51] vs. no comorbidities). In‑hospital mortality associated with COVID‑19 increased markedly with age, but comorbidities conferred substantial additional risk across all age groups, with particularly high relative risks in younger adults. These findings support the continued prioritization of older adults and targeted high‑risk groups, including younger patients with chronic conditions such as hypertension and diabetes, for preventive interventions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.